Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-

Gastric Acid*; Gastrointestinal Agents/*pharmacology ; Potassium/*pharmacology ; Pyrroles/*pharmacology ; Sulfonamides/*pharmacology; Adult ; Asian People ; Dose-Response Relationship, Drug ; Double-Blind Method ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Half-Life ; Humans ; Japan ; Male ; Metabolic Clearance Rate ; Middle Aged ; Nervous System Diseases ; Pyrroles/adverse effects ; Pyrroles/pharmacokinetics ; Sulfonamides/adverse effects ; Sulfonamides/pharmacokinetics ; United Kingdom ; White People ; Young Adult

Background: TAK-438 (vonoprazan) is a potassium-competitive acid blocker that reversibly inhibits gastric H(+) , K(+) -ATPase.
Aim: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-438 in healthy Japanese and non-Japanese men.
Methods: In two Phase I, randomised, double-blind, placebo-controlled studies, healthy men (Japan N = 60; UK N = 48) received TAK-438 10-40 mg once daily at a fixed dose level for 7 consecutive days. Assessments included safety, tolerability, pharmacokinetics and pharmacodynamics (intragastric pH).
Results: Plasma concentration-time profiles of TAK-438 at all dose levels showed rapid absorption (median Tmax ≤2 h). Mean elimination half-life was up to 9 h. Exposure was slightly greater than dose proportional, with no apparent time-dependent inhibition of metabolism. There was no important difference between the two studies in AUC0-tau on Day 7. TAK-438 caused dose-dependent acid suppression. On Day 7, mean 24-h intragastric pH>4 holding time ratio (HTR) with 40 mg TAK-438 was 100% (Japan) and 93.2% (UK), and mean night-time pH>4 HTR was 100% (Japan) and 90.4% (UK). TAK-438 was well tolerated. The frequency of adverse events was similar at all dose levels and there were no serious adverse events. There were no important increases in serum alanine transaminase activity. Serum gastrin and pepsinogen I and II concentrations increased with TAK-438 dose.
Conclusions: TAK-438 in multiple rising oral dose levels of 10-40 mg once daily for 7 days was safe and well tolerated in healthy men and caused rapid, profound and sustained suppression of gastric acid secretion throughout each 24-h dosing interval. Clinicaltrials.gov identifiers: NCT02123953 and NCT02141711.
(© 2015 The Authors. Alimentary Pharmacology and Therapeutics published by John Wiley & Sons Ltd.)

Cell Mol Life Sci. 2008 Jan;65(2):264-81. (PMID: 17928953)
Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:23-34. (PMID: 16700900)
Ther Clin Risk Manag. 2007 Aug;3(4):653-63. (PMID: 18472988)
J Med Chem. 2012 May 10;55(9):4446-56. (PMID: 22512618)
Aliment Pharmacol Ther. 2004 Aug 15;20(4):399-406. (PMID: 15298633)
J Clin Gastroenterol. 2007 Jul;41 Suppl 2:S226-42. (PMID: 17575528)
Dig Dis Sci. 1993 May;38(5):932-6. (PMID: 8482194)
Dig Dis Sci. 2007 Oct;52(10):2482-9. (PMID: 17415644)
J Pharmacol Exp Ther. 2011 Jun;337(3):797-804. (PMID: 21411494)
Expert Rev Clin Pharmacol. 2009 May;2(3):295-314. (PMID: 21822447)
J Pharmacol Exp Ther. 2010 Oct;335(1):231-8. (PMID: 20624992)
Aliment Pharmacol Ther. 2001 Jul;15(7):927-35. (PMID: 11421866)
Expert Rev Clin Pharmacol. 2009 Sep;2(5):461-468. (PMID: 21132072)
Digestion. 1992;51 Suppl 1:59-67. (PMID: 1397746)
Biochem Pharmacol. 2011 May 1;81(9):1145-51. (PMID: 21371447)
World J Gastroenterol. 2013 Oct 21;19(39):6529-35. (PMID: 24151377)
Bioorg Med Chem. 2012 Jun 15;20(12):3925-38. (PMID: 22579619)
Am J Gastroenterol. 2008 Jan;103(1):20-6. (PMID: 18184117)
MedGenMed. 2004;6(4):11. (PMID: 15775838)
Aliment Pharmacol Ther. 2005 Feb 15;21(4):455-63. (PMID: 15709997)
J Pharmacol Exp Ther. 2011 Nov;339(2):412-20. (PMID: 21828261)

ClinicalTrials.gov NCT02123953; NCT02141711

0 (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
0 (Gastrointestinal Agents)
0 (Pyrroles)
0 (Sulfonamides)
RWP5GA015D (Potassium)

Date Created: 20150225 Date Completed: 20150813 Latest Revision: 20221207

20231215

PMC4654261

10.1111/apt.13121

25707624